1
|
Bahl K, Senn JJ, Yuzhakov O, Bulychev A, Brito LA, Hassett KJ, Laska ME, Smith M, Almarsson Ö, Thompson J, Ribeiro AM, Watson M, Zaks T, Ciaramella G. Preclinical and Clinical Demonstration of Immunogenicity by mRNA Vaccines against H10N8 and H7N9 Influenza Viruses. Mol Ther 2017; 25:1316-1327. [PMID: 28457665 PMCID: PMC5475249 DOI: 10.1016/j.ymthe.2017.03.035] [Citation(s) in RCA: 411] [Impact Index Per Article: 58.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/23/2017] [Revised: 03/23/2017] [Accepted: 03/24/2017] [Indexed: 12/14/2022] Open
Abstract
Recently, the World Health Organization confirmed 120 new human cases of avian H7N9 influenza in China resulting in 37 deaths, highlighting the concern for a potential pandemic and the need for an effective, safe, and high-speed vaccine production platform. Production speed and scale of mRNA-based vaccines make them ideally suited to impede potential pandemic threats. Here we show that lipid nanoparticle (LNP)-formulated, modified mRNA vaccines, encoding hemagglutinin (HA) proteins of H10N8 (A/Jiangxi-Donghu/346/2013) or H7N9 (A/Anhui/1/2013), generated rapid and robust immune responses in mice, ferrets, and nonhuman primates, as measured by hemagglutination inhibition (HAI) and microneutralization (MN) assays. A single dose of H7N9 mRNA protected mice from a lethal challenge and reduced lung viral titers in ferrets. Interim results from a first-in-human, escalating-dose, phase 1 H10N8 study show very high seroconversion rates, demonstrating robust prophylactic immunity in humans. Adverse events (AEs) were mild or moderate with only a few severe and no serious events. These data show that LNP-formulated, modified mRNA vaccines can induce protective immunogenicity with acceptable tolerability profiles.
Collapse
MESH Headings
- Animals
- Antibodies, Viral/blood
- Antibodies, Viral/immunology
- Cell Line
- Disease Models, Animal
- Female
- Ferrets
- Gene Expression
- Humans
- Immunization
- Immunization Schedule
- Influenza A Virus, H10N8 Subtype/genetics
- Influenza A Virus, H10N8 Subtype/immunology
- Influenza A Virus, H7N9 Subtype/genetics
- Influenza A Virus, H7N9 Subtype/immunology
- Influenza Vaccines/administration & dosage
- Influenza Vaccines/adverse effects
- Influenza Vaccines/immunology
- Macaca fascicularis
- Male
- Mice
- Orthomyxoviridae Infections/prevention & control
- Protamines
- RNA, Messenger/administration & dosage
- RNA, Messenger/genetics
- RNA, Messenger/pharmacokinetics
- RNA, Viral
- Tissue Distribution
Collapse
Affiliation(s)
- Kapil Bahl
- Valera, A Moderna Venture, 500 Technology Square, Cambridge, MA 02139, USA
| | - Joe J Senn
- Moderna Therapeutics, 200 Technology Square, Cambridge, MA 02139, USA
| | - Olga Yuzhakov
- Valera, A Moderna Venture, 500 Technology Square, Cambridge, MA 02139, USA
| | - Alex Bulychev
- Moderna Therapeutics, 200 Technology Square, Cambridge, MA 02139, USA
| | - Luis A Brito
- Moderna Therapeutics, 200 Technology Square, Cambridge, MA 02139, USA
| | - Kimberly J Hassett
- Valera, A Moderna Venture, 500 Technology Square, Cambridge, MA 02139, USA
| | - Michael E Laska
- Moderna Therapeutics, 200 Technology Square, Cambridge, MA 02139, USA
| | - Mike Smith
- Moderna Therapeutics, 200 Technology Square, Cambridge, MA 02139, USA
| | - Örn Almarsson
- Moderna Therapeutics, 200 Technology Square, Cambridge, MA 02139, USA
| | - James Thompson
- Moderna Therapeutics, 200 Technology Square, Cambridge, MA 02139, USA
| | | | - Mike Watson
- Valera, A Moderna Venture, 500 Technology Square, Cambridge, MA 02139, USA
| | - Tal Zaks
- Moderna Therapeutics, 200 Technology Square, Cambridge, MA 02139, USA
| | | |
Collapse
|